# Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations

> **NCT01359449** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 123 (actual)

## Conditions studied

- Meningitis
- Meningococcal Infection

## Interventions

- **BIOLOGICAL:** Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®
- **BIOLOGICAL:** Meningococcal Group C Conjugate vaccine: MenC

## Key facts

- **NCT ID:** NCT01359449
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2012-07
- **Final completion:** 2012-11
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2016-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01359449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01359449, "Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01359449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*